BACKGROUND: We previously reported that prenatal alcohol-induced deficits in dentate gyrus (DG) long-term potentiation (LTP) are ameliorated by the histamine H3 receptor inverse agonist ABT-239. ABT-239 did not enhance LTP in control rats, suggesting that the possibility of a heightened H3 receptor-mediated inhibition of LTP in prenatal alcohol-exposed (PAE) offspring. METHODS: To further investigate this mechanism, we examined the effect of methimepip, a selective histamine H3 receptor agonist, on DG granule cell responses and LTP in saccharin control and PAE rats. Long-Evans rat dams voluntarily consumed either a 0 or 5% ethanol solution 4 hours each day throughout gestation. Adult male offspring from these dams were anesthetized with urethane and electrodes implanted into the entorhinal cortical perforant path and the DG. RESULTS: In control offspring, methimepip reduced the coupling of fast excitatory postsynaptic field potentials to population spikes (E-S coupling), the probability of glutamate release, as measured by paired-pulse ratio (PPR) and diminished DG LTP. Similar reductions in E-S coupling and LTP were observed in saline-treated PAE offspring. In contrast to the control group, methimepip did not exacerbate PAE-induced reductions in E-S coupling or LTP. CONCLUSIONS: While the effects of methimepip in control offspring were consistent with speculation of a PAE-induced enhancement of H3 receptor-mediated inhibition of E-S coupling and LTP, the absence of an added effect of methimepip in PAE offspring could indicate either an inability to further inhibit these responses with methimepip in PAE rats or the presence of more complex regulatory neural interactions with in vivo recordings in PAE rats. Follow-up studies of H3 receptor-mediated responses in DG slice preparations are under way to provide clearer insights into the role of the H3 receptor regulation of excitatory transmission in PAE rats.
BACKGROUND: We previously reported that prenatal alcohol-induced deficits in dentate gyrus (DG) long-term potentiation (LTP) are ameliorated by the histamine H3 receptor inverse agonist ABT-239. ABT-239 did not enhance LTP in control rats, suggesting that the possibility of a heightened H3 receptor-mediated inhibition of LTP in prenatal alcohol-exposed (PAE) offspring. METHODS: To further investigate this mechanism, we examined the effect of methimepip, a selective histamine H3 receptor agonist, on DG granule cell responses and LTP in saccharin control and PAErats. Long-Evans rat dams voluntarily consumed either a 0 or 5% ethanol solution 4 hours each day throughout gestation. Adult male offspring from these dams were anesthetized with urethane and electrodes implanted into the entorhinal cortical perforant path and the DG. RESULTS: In control offspring, methimepip reduced the coupling of fast excitatory postsynaptic field potentials to population spikes (E-S coupling), the probability of glutamate release, as measured by paired-pulse ratio (PPR) and diminished DG LTP. Similar reductions in E-S coupling and LTP were observed in saline-treated PAE offspring. In contrast to the control group, methimepip did not exacerbate PAE-induced reductions in E-S coupling or LTP. CONCLUSIONS: While the effects of methimepip in control offspring were consistent with speculation of a PAE-induced enhancement of H3 receptor-mediated inhibition of E-S coupling and LTP, the absence of an added effect of methimepip in PAE offspring could indicate either an inability to further inhibit these responses with methimepip in PAErats or the presence of more complex regulatory neural interactions with in vivo recordings in PAErats. Follow-up studies of H3 receptor-mediated responses in DG slice preparations are under way to provide clearer insights into the role of the H3 receptor regulation of excitatory transmission in PAErats.
Authors: S Morisset; A Rouleau; X Ligneau; F Gbahou; J Tardivel-Lacombe; H Stark; W Schunack; C R Ganellin; J C Schwartz; J M Arrang Journal: Nature Date: 2000-12-14 Impact factor: 49.962
Authors: Peter Jedlicka; Mrinalini Hoon; Theofilos Papadopoulos; Andreas Vlachos; Raphael Winkels; Alexandros Poulopoulos; Heinrich Betz; Thomas Deller; Nils Brose; Frédérique Varoqueaux; Stephan W Schwarzacher Journal: Cereb Cortex Date: 2010-06-07 Impact factor: 5.357
Authors: P Blandina; M Giorgetti; L Bartolini; M Cecchi; H Timmerman; R Leurs; G Pepeu; M G Giovannini Journal: Br J Pharmacol Date: 1996-12 Impact factor: 8.739
Authors: Gerard B Fox; Timothy A Esbenshade; Jia Bao Pan; Richard J Radek; Kathleen M Krueger; Betty B Yao; Kaitlin E Browman; Michael J Buckley; Michael E Ballard; Victoria A Komater; Holly Miner; Min Zhang; Ramin Faghih; Lynne E Rueter; R Scott Bitner; Karla U Drescher; Jill Wetter; Kennan Marsh; Martine Lemaire; Roger D Porsolt; Youssef L Bennani; James P Sullivan; Marlon D Cowart; Michael W Decker; Arthur A Hancock Journal: J Pharmacol Exp Ther Date: 2004-12-17 Impact factor: 4.030
Authors: Ruggero Galici; Jamin D Boggs; Leah Aluisio; Ian C Fraser; Pascal Bonaventure; Brian Lord; Timothy W Lovenberg Journal: Neuropharmacology Date: 2009-04-02 Impact factor: 5.250
Authors: Rafael K Varaschin; Nyika A Allen; Martina J Rosenberg; C Fernando Valenzuela; Daniel D Savage Journal: Alcohol Clin Exp Res Date: 2018-01-08 Impact factor: 3.455
Authors: Lilliana M Sanchez; Jonathan Goss; Jennifer Wagner; Suzy Davies; Daniel D Savage; Derek A Hamilton; Benjamin J Clark Journal: Behav Brain Res Date: 2018-12-07 Impact factor: 3.332
Authors: Clark W Bird; Felicha T Candelaria-Cook; Christy M Magcalas; Suzy Davies; C Fernando Valenzuela; Daniel D Savage; Derek A Hamilton Journal: PLoS One Date: 2015-03-06 Impact factor: 3.240